Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Males Clear all

Conditions: Opioid Use Disorder
Interventions: [14C]IDV184001AN; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Adults
Interventions: EC5026 oral capsule, Placebo oral capsule; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Blood Loss, Healthy
Interventions: CM-1500; Device
Lead sponsor: Zynex Monitoring Solutions; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers, Healthy
Interventions: GC4419; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Renal Impairment, Healthy Volunteers
Interventions: rilzabrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Healthy Adults
Interventions: methylnaltrexone, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Healthy
Interventions: JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Calcium Oxalate Urolithiasis
Interventions: Moderately high oxalate/low calcium diet non-colonized, Oxalobacter formigenes, Moderately high oxalate/low calcium diet colonized; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult, Healthy Male and Female Subjects, Healthy Subjects, Healthy Volunteers Only, Healthy Non-smokers
Interventions: Negative control, Avocado, Fat and fiber addition; Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Healthy Volunteers
Interventions: HSV529, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: RDEA3170, 10 mg, RDEA3170, 2.5 mg, RDEA3170, 5 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Renal Disease, End-Stage, Renal Insufficiency, Chronic, Renal Insufficiency, Acute
Interventions: Bosutinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: DeLand, Florida • Gainesville, Florida • Miami, Florida + 2 more

Conditions: Healthy Adult Male, Healthy Adult Females, Joint Discomfort
Interventions: Olive Oil Extract, Placebo; Dietary Supplement
Lead sponsor: Applied Food Sciences Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Corneal Neovascularization
Interventions: KDR2-2, Placebo; Drug
Lead sponsor: Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: Open-label TRV734 125 mg, TRV734 blinded, Oxycodone IR 10 mg, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Allergic Contact Dermatitis
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Wright State Physicians; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Drug Interaction Potentiation
Interventions: PA21, Warfarin; Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Cancer, Prostate Cancer
Interventions: Health coordinator (or patient navigator), Educational materials only; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 65 Years and older
Enrollment: 2,593 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Severe Renal Impairment
Interventions: Pitavastatin 4mg; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Male Volunteers
Interventions: Oral [14C] PF-07799544, Oral Unlabeled PF-07799544, IV [14C] PF-07799544; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions: NMN and TMG (Euexia), Nicotinamide Mononucleotide (NMN), Placebo; Dietary Supplement
Lead sponsor: Scott Silveira; Other
Eligibility: 60 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Healthy
Interventions: Wild ginseng extract, Placebo; Dietary Supplement
Lead sponsor: Texas A&M University San Antonio; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion

Avocado and Postprandial Responses

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

RDEA3170 Tablet and Capsule Bioavailability Study

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Bosutinib In Subjects With Renal Impairment

Examining Olive Oil Extract on Knee Comfort and Function

Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment

A Safety, Tolerability, PD and PK Study in Healthy Adults

Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

A Drug-Drug Interaction Study of Warfarin and PA21

Partnership for Healthy Seniors

Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers

A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

The Investigators Conducted a Study to Examine the Impact of Wild Ginseng Extract (WG) on Exercise Performance, Cognitive Function, and Fatigue Recovery Among Twelve Healthy Adult Males